Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26N2O3 |
Molecular Weight | 354.4427 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]3([H])N(CCC4=C3NC5=C4C=CC=C5)C2
InChI
InChIKey=BLGXFZZNTVWLAY-SCYLSFHTSA-N
InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1
DescriptionSources: https://www.drugs.com/cdi/yohimbine.htmlCurator's Comment: description was created based on several sources, including
http://www.fatburner-1.com/fatburner/yohimbin-kaufen.html
https://www.ncbi.nlm.nih.gov/pubmed/10611634
Sources: https://www.drugs.com/cdi/yohimbine.html
Curator's Comment: description was created based on several sources, including
http://www.fatburner-1.com/fatburner/yohimbin-kaufen.html
https://www.ncbi.nlm.nih.gov/pubmed/10611634
Yohimbine is a plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. The exact mechanism for its use in impotence has not been fully elucidated. Yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, partial agonist actions at h5-HT(1A) sites. Yohimbine-mediated norepinephrine release at the level of the corporeal tissues may also be involved. In addition, beneficial effects may involve other neurotransmitters such as dopamine and serotonin and cholinergic receptors. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalmic center and release of posterior pituitary hormone. Reportedly yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by (beta)-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it; however, no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage. Side effect of Yohimbine include anxiety, tremor, palpitations, diarrhea, and supine hypertension.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10611634 |
|||
Target ID: CHEMBL2095230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10611634 |
|||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10611634 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Gastroprokinetic effect and mechanism of SK-896, a new motilin analogue, during the interdigestive period in conscious dogs. | 2001 |
|
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. | 2001 |
|
[Agmatine inhibits the afferent activity of carotid baroreceptor in rats]. | 2001 Apr |
|
Role of the alpha(1)- and alpha(2)-adrenoceptors of the paraventricular nucleus on the water and salt intake, renal excretion, and arterial pressure induced by angiotensin II injection into the medial septal area. | 2001 Apr |
|
Efficacy of 1.25% amitraz solution in the treatment of generalized demodicosis (eight cases) and sarcoptic mange (five cases) in dogs. | 2001 Apr |
|
Inhibition of field stimulation-induced contractions of rabbit vas deferens by muscarinic receptor agonists: selectivity of McN-A-343 for M1 receptors. | 2001 Apr |
|
Nitric oxide attenuates alpha(2)-adrenergic receptors by ADP-ribosylation of G(i)alpha in ciliary epithelium. | 2001 Aug |
|
Yohimbine for anxiety disorders. | 2001 Aug |
|
An isobolographic analysis of the adrenergic modulation of diclofenac antinociception. | 2001 Aug |
|
Insulin secretion and glucose kinetics during exercise with and without pharmacological alpha(1)- and alpha(2)-receptor blockade. | 2001 Aug |
|
High concentrations of adrenergic antagonists prolong sciatic nerve blockade by tetrodotoxin. | 2001 Aug |
|
Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. | 2001 Aug |
|
Differential role of adrenoceptors in control of plasma glucose and fatty acids in carp, Cyprinus carpio (L.). | 2001 Aug |
|
Microinjection of carbachol in the lateral hypothalamus produces opposing actions on nociception mediated by alpha(1)- and alpha(2)-adrenoceptors. | 2001 Aug 17 |
|
Visceral antinociception produced by bee venom stimulation of the Zhongwan acupuncture point in mice: role of alpha(2) adrenoceptors. | 2001 Aug 3 |
|
Phentolamine mesylate relaxes rabbit corpus cavernosum by a nonadrenergic, noncholinergic mechanism. | 2001 Feb |
|
Hydroxylation of yohimbine in superacidic media: one-step access to human metabolites 10 and 11-hydroxyyohimbine. | 2001 Feb |
|
Presynaptic alpha2-adrenoceptor-mediated modulation of adenosine 5' triphosphate and noradrenaline corelease: differences in canine mesenteric artery and vein. | 2001 Feb |
|
The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats. | 2001 Jan |
|
Alpha 2-adrenoceptor activity induces the antidepressant-like glycolipid in mouse forced swimming. | 2001 Jan-Feb |
|
Bradykinin and electrical stimulation increase prostaglandin production in the rat vas deferens. | 2001 Jul |
|
Disturbance of the prejunctional modulation of cholinergic neurotransmission during chronic granulomatous inflammation of the mouse ileum. | 2001 Jul |
|
Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogenesis: interactions with a beta3-adrenergic agonist in rats. | 2001 Jul |
|
Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology. | 2001 Jul |
|
Activation of alpha(2)-receptors in the rostral ventrolateral medulla evokes natriuresis by a renal nerve mechanism. | 2001 Jul |
|
Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. | 2001 Jul |
|
The effect of adrenergic compounds on neurogenic dural vasodilatation. | 2001 Jul 13 |
|
The role of Kupffer cell alpha(2)-adrenoceptors in norepinephrine-induced TNF-alpha production. | 2001 Jul 27 |
|
The influence of chloroethylclonidine-induced contraction in isolated arteries of Wistar Kyoto rats: alpha1D- and alpha1A-adrenoceptors, protein kinase C, and calcium influx. | 2001 Jul-Aug |
|
Alpha2-adrenoceptors inhibit antidiuretic hormone-stimulated Na+ absorption across tight epithelia (Rana esculenta). | 2001 Jun |
|
An obligatory role for spinal cholinergic neurons in the antiallodynic effects of clonidine after peripheral nerve injury. | 2001 Jun |
|
The alpha 2 adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats. | 2001 Jun |
|
Immunoaffinity purification and reconstitution of human alpha(2)-adrenergic receptor subtype C2 into phospholipid vesicles. | 2001 Jun |
|
Comparison of the effect of intrathecal administration of clonidine and yohimbine on the locomotion of intact and spinal cats. | 2001 Jun |
|
Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. | 2001 Jun |
|
Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline. | 2001 Jun 1 |
|
Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. | 2001 Mar |
|
Effect of electrical field stimulation on insulin and glucagon secretion from the pancreas of normal and diabetic rats. | 2001 May |
|
In vivo assessment of the regulatory mechanism of cholinergic neuronal activity associated with motility in dog small intestine. | 2001 May |
|
Brimonidine and inhibition of nitrite production in isolated porcine ciliary processes. | 2001 May |
|
Oral drug therapy for erectile dysfunction. | 2001 May |
|
The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine. | 2001 May |
|
Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice. | 2001 May |
|
Pharmacological aids to locomotor training after spinal injury in the cat. | 2001 May 15 |
|
Agmatine produces antinociception in tonic pain in mice. | 2001 May-Jun |
|
Neuropeptide Y in obese women during treatment with adrenergic modulation drugs. | 2001 May-Jun |
|
Effects of alpha(2)-adrenergic agonists on lipopolysaccharide-induced aqueous flare elevation in pigmented rabbits. | 2001 May-Jun |
|
Effects of adrenergic agonists and antagonists on tetrodotoxin-induced nerve block. | 2001 May-Jun |
|
Alpha-2 and beta-adrenergic receptors mediate NE's biphasic effects on rat thick ascending limb chloride flux. | 2001 Sep |
|
Dopamine inhibits vasopressin action in the rat inner medullary collecting duct via alpha(2)-adrenoceptors. | 2001 Sep |
Sample Use Guides
2 single-dose administrations of 5 mg yohimbine hydrochloride at least one week i.e. 6 treatment free days between all administrations
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1665013
In order to test the putative role of alpha 2 receptors in ethanol intoxication, it was studied the interaction between ethanol and yohimbine on the spontaneous firing rate of rat locus coeruleus (LC) in an in vitro slice model. If yohimbine (20 microM) was simultaneously perfused, the ethanol-induced inhibition was rapidly antagonized. This effect is reversible after long time washout of yohimbine.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.2670
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
WHO-VATC |
QV03AB93
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
WHO-ATC |
G04BE04
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
CFR |
21 CFR 310.528
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
WHO-VATC |
QG04BE04
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
||
|
DSLD |
2366 (Number of products:175)
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9040130
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
3659
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
C77304
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
205-672-0
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
m11570
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB15744MIG
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
2Y49VWD90Q
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
DB01392
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
2Y49VWD90Q
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
146-48-5
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
D015016
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
10093
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
YOHIMBINE
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
102
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
8969
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
100000076753
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | |||
|
220982
Created by
admin on Fri Dec 15 15:24:57 GMT 2023 , Edited by admin on Fri Dec 15 15:24:57 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)